Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2009, vol. 18, nr 4, July-August, p. 323–328

Publication type: original article

Language: English

How Does Resveratrol Change Some Metabolic and Circulatory Parameters? A Preliminary Study

Zmiany niektórych wskaźników krążenia i metabolicznych wywołane przez resveratrol – badanie wstęp

Pelin Aribal1,, Güzin Özelci Kavas1,, Ulas Coban1,, Atilla Halil Elhan2,

1 Department of Pathophysiology, Faculty of Medicine, Ankara University, Turkey

2 Department of Biostatistic and Medical Informatics, Faculty of Medicine, Ankara University, Turkey

Abstract

Objectives. Resveratrol is a natural polyphenol present in red wine and various foods. The aim of this study was to investigate its effects on body weight, several biochemical parameters, blood pressure, and heart rate in rats.
Material and Methods. In this preliminary study, rats were divided into two equal groups according to body weight (n = 20 each) to investigate the effects of resveratrol on two different weight groups, one relatively higher than the other. The first group constituted 10− to 12−week−old male Sprague−Dawley rats with a mean body weight of 235 g and the second rats weighing approximately 284 g. Both groups were divided into control (n = 10) and experimental (n = 10) groups. In the two experimental groups, resveratrol was administered (20 mg/kg) in drinking water for 24 weeks. After one week of training, systolic arterial blood pressure and heart rate were recorded in all the groups. Changes due to resveratrol administration in body weight and blood glucose, total cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma−glutamyl transpeptidase (GGT), and uric acid (UA) levels were compared with the controls.
Results. There were statistically significant decreases in weight gain, total cholesterol, and blood pressure in both experimental groups. In the lighter group, ALT level (p = 0.003) and in the heavier ALP (p = 0.049) and UA levels (p = 0.030) were decreased slightly compared with the controls.
Conclusion. The results suggest that resveratrol ameliorated total cholesterol levels and decreased body weights with subsequent changes in systolic blood pressure while not leading to any deterioration in biochemical parameters.

Streszczenie

Cel pracy. Resveratrol jest naturalnym polifenolem obecnym w czerwonym winie i produktach spożywczych. Celem pracy była ocena jego wpływu na masę ciała, wskaźniki biochemiczne, ciśnienie krwi i tętno u szczurów.
Materiał i metody. We wstępnym badaniu szczury podzielono na 2 grupy odpowiadające pod względem masy ciała (n = 20), aby ocenić wpływ resveratrolu na 2 różne grupy mas, jedna istotnie większa od drugiej. Do pierwszej grupy włączono 10–12−tygodniowe szczury Sprague−Dawley ze średnią masą ciała 235 g, a do drugiej szczury ważące średnio 284 g. Obie grupy podzielono na kontrolną (n = 10) i badaną (n = 10). W obu grupach badanych resveratrol (20 mg/kg) podawano przez 24 tygodnie w wodzie pitnej. Po tygodniu treningu zmierzono skurczowe ciśnienie krwi i tętno we wszystkich grupach. Zmiany wywołane podaniem resveratrolu masy ciała, glukozy we krwi, całkowitego cholesterolu, aminotransferazy asparaginianowej AST, aminotransferazy alaninowej ALT, fosfatazy alkalicznej ALP, gamma−glutamylotransferazy GGT, kwasu moczowego porównano z grupą kontrolną.
Wyniki. Zanotowano istotnie statystycznie zmniejszenie masy ciała, całkowitego cholesterolu i ciśnienia krwi w obu grupach badanych. W grupie z mniejszą masą ciała stężenie ALT (p = 0,003), a w grupie z większą masą ALP (p = 0,049) i kwas moczowy (p = 0,30) były mniejsze w porównaniu z grupą kontrolną.
Wnioski. Wyniki sugerują, że resveratrol poprawił stężenie całkowitego cholesterolu i zmniejszył masę ciała wraz z następującymi zmianami skurczowego ciśnienia krwi, ale nie doprowadził do pogorszenia wskaźników biochemicznych.

Key words

resveratrol, cholesterol, blood pressure, heart rate, body weight

Słowa kluczowe

resveratrol, cholesterol, ciśnienie krwi, tętno, masa ciała

References (39)

  1. Soleas GJ, Diamandis EP, Goldberg DM: Resveratrol: a molecule whose time has come? and gone? Clin Biochem 1997, 30(2), 91–113.
  2. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004, 24(5A), 2783–2840.
  3. Gehm BD, McAndrews JM, Chien PY, Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997, 94(25), 14138–14143.
  4. Haider UG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM: Resveratrol increases serine15−phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum−activated vascular smooth muscle cells. Mol Pharmacol 2003, 63(4), 925–932.
  5. Duffy SJ, Vita JA: Effects of phenolics on vascular endothelial function. Curr Opin Lipidol 2003, 14(1), 21–27.
  6. Klinge CM, Blankenship KA, Risinger KE et al.: Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 2004, 280(9), 7460–7468.
  7. Brito P, Almeida LM, Dinis TC: The interaction of resveratrol with ferrylmyoglobin and peroxynitrite; protection against LDL oxidation. Free Radic Res 2002, 36(6), 621–631.
  8. Jang M, Cai L, Udeani GO et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275(5297), 218–220.
  9. Howitz KT, Bitterman KJ, Cohen HY et al.: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954), 191–196.
  10. Barefoot JC, Gronbaek M, Feaganes JR, McPherson RS, Williams RB, Siegler IC: Alcoholic beverage preference, diet, and health habits in the UNC Alumni Heart Study. Am J Clin Nutr 2002, 76(2), 466–472.
  11. Mc Cann SE, Sempos C, Freudenheim JL et al.: Alcoholic beverage preference and characteristics of drinkers and nondrinkers in western New York (United States). Nutr Metab Cardiovasc Dis 2003, 13(1), 2–11.
  12. Chen Y, Tseng SH: Review. Proand anti−angiogenesis effects of resveratrol. In Vivo 2007, 21(2), 365–370.
  13. Igura K, Ohta T, Kuroda Y, Kaji K: Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 2001, 171(1), 11–16.
  14. Lin MT, Yen ML, Lin CY, Kuo ML: Inhibition of vascular endothelial growth factor−induced angiogenesis by resveratrol through interruption of Src−dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 2003, 64(5), 1029–1036.
  15. Steele VE, Hawk ET, Viner JL, Lubet RA: Mechanisms and applications of non−steroidal anti−inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003, 523–524, 137–144.
  16. Olas B, Nowak P, Kolodziejczyk J, Ponczek M, Wachowicz B: Protective effects of resveratrol against oxidative/nitrative modifications of plasma proteins and lipids exposed to peroxynitrite. J Nutr Biochem 2006, 17, 96–102.
  17. Conover WJ: Practical Nonparametric Statistics 2nd Ed., 1980. John Wiley & Sons, New York. Chapter 5 Some methods based on ranks, Section 5.2 Several independent samples. 229–239.
  18. Faxon DP, Fuster V, Libby P et al.: Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation 2004, 109(21), 2617–2625.
  19. Wannamethee SG, Shaper AG: Type of alcoholic drink and risk of major coronary heart disease events and allcause mortality. Am J Public Health 1999, 89(5), 685–690.
  20. Kyselova V, Peknicova J, Buckiova D, Boubelik M: Effects of p−nonylphenol and resveratrol on body and organ weight and in vivo fertility of outbred CD−1 mice. Reprod Biol Endocrinol 2003, 1, 30.
  21. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argilés J, López−Soriano F: Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Letters 2007, 245(1–2), 144–148.
  22. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD: Is Resveratrol an Estrogen Agonist in Growing Rats? Endocrinology 1999, 140(1), 50–54.
  23. Mgbonyebi OP, Russo J, Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 1998, 12, 865–869.
  24. Pozo−Guisado E, Alvarez−Barrientos A, Mulero−Navarro S, Santiago−Josefat B, Fernandez−Salguero PM: The antiproliferative activity of resveratrol results in apoptosis in MCF−7 but not in MDA−MB−231 human breast cancer cells: cell−specific alteration of the cell cycle. Biochem Pharmacol 2002, 64, 1375–1386.
  25. Wu SL, Yu L, Meng KW, Ma ZH, Pan CE: Resveratrol prolongs allograft survival after liver transplantation in rats. World J Gastroenterol 2005, 11(30), 4745–4749.
  26. Lieber CS, Herman Award Lecture. A personal perspective on alcohol, nutrition, and the liver. Am J Clin Nutr 1993, 58, 430–442.
  27. Nunez O, Fernandez−Martínez A, Majano PL, Apolinario A, Gomez−Gonzalo M, Benedicto I, LopezCabrera M, Bosca L, Clemente G, Garcia−Monzon C, Martin−Sanz P: Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A. Gut 2004, 53, 1665–72.
  28. Venkatachalam K, Mummidi S, Cortez DM, Prabhu SD, Valente AJ, Chandrasekar B: Resveratrol inhibits high glucose−induced PI3K/AKT/ERK−dependent interleukin−17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2008, 294(5), H2078–2087.
  29. Baur J at al.: Resveratrol improves health and survival of mice on a high−calorie diet. Nature 2006, 444, 337–342.
  30. Vitaglione P, Sforza S, Galaverna G et al.: Bioavailability of trans−resveratrol from red wine in humans. Mol Nutr Food Res 2005, 49(5), 495–504.
  31. Gescher AJ, Steward WP: Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 2003, 12(10), 953–957.
  32. Stojanovic S, Sprinz H, Brede O: Efficiency and mechanism of the antioxidant action of trans−resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 2001, 391(1), 79–89.
  33. Pal S, Naissides M, Mamo J: Polyphenolics and fat absorption. Int J Obes 2004, 28, 324–326.
  34. Martin AR, Villegas I, La Casa C, Alarcon de la Lastra C: Resveratrol, apolyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004, 67, 1399–1410.
  35. Pal S, Ho N, Santos C, Dubois P, Mamo J, Croft K, Allister E: Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr 2003, 133, 700–706.
  36. Naissides M, James T, Mamo J, Pal S. The chronic effects of red wine polyphenolics on cardiovascular risk factors in postmenopausal women. Atherosclerosis 2006, 185, 2, 438–445.
  37. Zhaoping L, Yan S, Xiaopeng Z, Zeqing L, Wenzhong Z, Weifeng M, Wei W, Wenming C, Xin Z, Xudong J, Ning L, Chi H, Changxing L: Effects of trans−resveratrol on hypertension−induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharm Physiol 2005, 32(12), 1049–1054.
  38. Gumanova NG, Artyushkova EB, Metel’skaya VA, Kochkarov VI, Pokrovskaya TG, Danilenko LM, Korneev MM, Pokrovskii MV, Pashin EN: Effect of antioxidants pQ510 and resveratrol on regulatory function of the endothelium in rats with modeled arterial hypertension. Bull Exp Biol Med 2007, 143(6), 678–681.
  39. Rush JWE, Quadrilatero J, Levy AS, Ford RJ: Chronic resveratrol enhances endothelium−dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp Biol Med 2007, 232, 814–822.
© Wroclaw Medical University